Medtech Impact Symposium & Gala

Partha Paul is a seasoned healthcare and medical device executive with extensive experience in business development, strategic planning, and commercialization across medtech, biotechnology, and healthcare sectors. Partha has contributed to advancements in medical devices, diagnostics, and life sciences through leadership roles in both early-stage ventures and global corporations.

Currently, Partha serves at Cleveland Clinic, where he focuses on identifying strategic partners and advancing novel medical technologies toward market readiness. He fosters collaborations, guides intellectual property strategy, and attracts industry interest to support the development of innovative solutions across multiple therapy areas.

Previously, Partha was Vice President of Business Development at Leuko, a Boston-based company pioneering the first non-invasive white blood cell assessment device. He defined go-to-market strategies, established market access plans, forged partnerships, and led fundraising efforts to commercialize this transformative technology. As Head of North America Business at LPixel Inc., Partha spearheaded FDA approval for AI-driven diagnostic devices, advanced oncology and neurology diagnostics, and built partnerships with device and pharmaceutical companies. At Philips, Partha managed $100M P&L in image-guided therapy devices, achieving strong revenue growth and market share. At GE Healthcare, he led strategic initiatives to significantly expand a $350M portfolio in imaging and molecular diagnostics, driving acquisitions and partnerships. Earlier, he held leadership roles at Interleukin Genetics, AtheroGenics, and Southwest Research Institute, executing high-value deals and building new businesses.

As a mentor for MassBIO and Johns Hopkins, Partha continues to guide medtech startups toward success, leveraging his expertise in market access, strategic partnerships, and commercialization strategies.

Katie Hathaway has served as Senior Director and Global Head, Government Affairs, Advocacy & Public Policy since January 2025.
Katie is a longtime advocacy professional, disability rights attorney, and national expert on the rights of people with diabetes. Katie joins
Insulet from a career protecting and advancing the rights of people with diabetes to live free from discrimination as Vice President of
Legal Advocacy at the American Diabetes Association, where she combined legal and medical expertise to open career paths, make
schools safer, and ensure equal access and appropriate treatment for people with diabetes. Most recently, she served as a strategic
advisor for mission-focused national health organizations working to improve access to healthcare and close the justice gap for
marginalized communities. Katie holds a Juris Doctor degree from Catholic University and a Bachelor’s degree in Political Science from
Saint Michael’s College

Dr. Jon Bloom is a board-certified physician and entrepreneur with over 20 years of experience in technology development, patient monitoring, biomedical research, and health care delivery. He co-founded Podimetrics in 2011 while a student at the MIT Sloan School of Management, and he’s served as our CEO ever since. Dr. Bloom was first inspired to create a solution to help prevent diabetic amputations while practicing anesthesia; he frequently treated patients who required foot amputations and knew there had to be a less drastic way to prevent diabetic foot complications. He previously served as a Clinical Assistant Professor and staff anesthesiologist at the University of Pittsburgh Medical Center, and as the Director of Global Medical Affairs for Covidien’s Respiratory and Monitoring Solutions division. Dr. Bloom has co-authored more than 20 peer-reviewed publications with a primary focus on health care economics and perioperative complications. He earned his medical degree from the University of Pittsburgh School of Medicine and completed his residency at Massachusetts General Hospital.

Avik Roy is Co-Founder and Chairman of the Foundation for Research on Equal Opportunity, a non-partisan, non-profit think tank focused on improving the lives of Americans on the bottom half of the economic ladder using freedom, innovation, and pluralism. He also serves as Chairman of Clinivanta, a healthcare company focused on prevention of cardiovascular disease.

National Review has called him one of the nation’s “sharpest policy minds,” while the New York Times’ Paul Krugman described him as man of “personal and moral courage.” NBC’s Chuck Todd, on Meet the Press, said Roy was one “of the most thoughtful guys [who has] been debating” health care reform.

Roy is best known for his plan to achieve universal coverage through private health insurance, which has been introduced in Congress as the Fair Care Act. He serves on advisory boards of the National Academy of Medicine, the Peterson Center on Healthcare, the University of Pennsylvania, and other organizations; is a Senior Advisor to the Bipartisan Policy Center; co-chaired the Fixing Veterans Health Care Policy Taskforce; and has served as a policy advisor to several presidential candidates, including Mitt Romney, Rick Perry, and Marco Rubio.

Along with Forbes, where Roy served as the Opinion and Policy Editor for a decade, Roy’s writing has appeared in The Wall Street Journal, The New York Times, The Washington Post, USA Today, and The Atlantic. He has appeared on numerous national television programs, including PBS NewsHour, Meet the Press, Face the Nation, and Real Time with Bill Maher.

Previously, Roy served as President of the National Institute for Health Care Management, as an Aspen Institute Health Innovators Fellow, and as a health care investor at Bain Capital, J.P. Morgan, and other firms. He serves on the boards of CrowdHealth and the Texas Bitcoin Foundation, and as Chief Strategy Officer at Strive, an asset management firm in Texas.

He was born and raised near Detroit, Michigan, and graduated from high school in San Antonio, Texas. Roy was educated at the Massachusetts Institute of Technology, where he studied molecular biology, and the Yale University School of Medicine.

Rachel Ann Robinson is the Chief Operating Officer of the Massachusetts Medical Device Industry Council (MassMEDIC), the leading MedTech association representing hundreds of companies across the New England medical technology ecosystem. She works closely with entrepreneurs, industry leaders, and policymakers to support collaboration and innovation in the development of life-changing medical technologies.

Robinson frequently convenes and moderates discussions with leaders across the healthcare and MedTech sectors, bringing together diverse perspectives on innovation, regulation, investment, and the evolving healthcare landscape. Through her work, she helps strengthen connections across the industry and fosters dialogue that advances the future of medical technology and patient care.

Cam Hicks is an Executive Officer and the Corporate Vice President & Chief Human Resources Officer for Teleflex, a $2.9bn global medical technology company with over 15,000 employees manufacturing/selling in 150 countries. Cam joined Teleflex in April of 2013, bringing his more than 23 years of global experience in Human Resources and Organizational Development.

Prior to joining Teleflex, Cam served as the Executive Vice President of Human Resources & Organizational Effectiveness for Harlan Laboratories, a private global provider of pre-clinical and non-clinical research services. Preceding Harlan, he spent 20 years at MDS where he was the Senior Vice President of Human Resources for the global Pharma Services division, the Director of Human Resources for the Canadian Diagnostics division, and held a variety of other HR and Operational Leadership roles. Prior to joining MDS, Cam was on the teaching faculty at the Richard Ivey School of Business in Canada.

Cam was selectively recognized by his Philadelphia/New Jersey/Delaware peers as “CHRO of the Year” in 2018, and with a “Lifetime Achievement Award” in 2021. Cam is a Certified Director with the National Association of Corporate Directors (NACD), earned the Certificate in Cyber-Risk Oversight from Carnegie Mellon University and the NACD, and currently serves on a variety of non-profit Boards. He earned his B.A. in Honors Business Administration from the Ivey School of Business in Canada.

Cam and his wife Nancy have been married for 35 years, and currently live in Wayne, Pennsylvania. Cam enjoys distance running (completed five marathons), and has an Associate Degree in Piano Performance from the Western Conservatory of Music (Canada). Nancy is a graduate (lyric soprano) of the University of Toronto’s Faculty of Music, and currently works as a communications coach/consultant and an On-Air Talent with QVC. They have two sons, a daughter-in-law, and two grandsons.

Desmond is President of Gentuity, where he leads the company’s mission to advance intravascular imaging and enable interventional cardiologists to deliver more precise, patient-centered care. Since joining Gentuity in 2021, he has focused on driving the convergence of high-resolution imaging, artificial intelligence, and intuitive system design to bring next-generation tools into routine clinical practice.

With more than 20 years of experience in biomedical optics, Desmond has played a key role in the development and launch of medical technologies across cardiology, ophthalmology, gastroenterology, and pulmonology. During his time at LightLab Imaging and St. Jude Medical, he led the development of earlier generations of intravascular imaging systems. He also served as General Manager and Vice President of R&D for Corneal Health at Glaukos Corp., overseeing the development and commercialization of drug-device combination therapies for rare ophthalmic diseases.

Desmond is passionate about the role of medical technology in improving patient outcomes while also experiencing lifelong learning, enjoying professional growth, and forming personal bonds with exceptional individuals from all over the world. He holds a Bachelor of Science in Electrical Engineering from the University of Alberta and a PhD in Electrical Engineering and Computer Science from MIT.

Emily Richardson leads Global Marketing and Product Management at Rapid Medical, where she has built and scaled the company’s marketing organization since 2020. She brings nearly two decades of experience in MedTech, focused on minimally invasive surgical and neurovascular devices. Her expertise spans product and portfolio strategy, global commercialization, and driving adoption of advanced technologies.

Mrs. Richardson has held leadership roles at Covidien (Medtronic), Johnson & Johnson, Medrobotics, and Penumbra, and brings global commercial experience across North America, Europe, and Asia. She holds dual degrees in Molecular and Cellular Biology and Kinesiology from the University of Illinois.

Teresa Prego is the Chief Executive Officer of EpiWatch, an innovative company bringing continuous seizure monitoring, detecting and alerting to individuals and families living with epilepsy. EpiWatch is an FDA cleared SaMD (software as a medical device) platform running on an Apple Watch, providing real-world, objective seizure data that improves safety, care management, and ultimately risk forecasting and precision medicine for epilepsy. Previously, she was Chief Commercial Officer for Nile AI, a digital care company focused on expanding access to care and changing care for people with epilepsy through access and information between clinician, caregiver and patients. She has led the introduction and commercialization of multiple disruptive products and services in the healthcare industry, including digital health offerings in neurology and primary care (PKG Health, Nile AI), surgical robotics for neurosurgical and orthopedic application (ROSA, acquired by Zimmer Biomet); ablation technologies with oncology and neurologic application; neurostimulation, and virtual care and services for targeted populations. Her passion is utilizing innovation to create improved care solutions and expand access to care.

Teresa has a BS in Engineering and Earth Sciences from the University of Notre Dame, and an MBA from the Carroll School of Management at Boston College. She has worked extensively in healthcare, medical device and human services, and has led multiple industry consortiums focused on increasing access and quality of care. She is on the Board of Directors for the Hidden Truths Project, a non-profit focused on combining artistic expression and celebrating individuals with differences, including ‘hidden’ disabilities like epilepsy. She also serves as a member of the community board for the Epilepsy Foundation of New England, and is a board director for Beyond Soccer, a program emphasizing soccer training and academics for kid in the greater Lawrence community of Massachusetts.

Justin Kelly currently serves as Noctrix Health’s Senior Vice President, Patient Access where he oversees market access strategy, government relations and reimbursement operations. Justin joined Noctrix Health in June 2023. Prior to joining Noctrix Health, Justin had extensive experience launching novel therapies and medical devices leading reimbursement and market access functions at Novocure, Sirtex Medical, Insulet Corporation and Genzyme Biosurgery. He holds a Master’s Degree in Global Business Administration from the Fletcher School at Tufts University as well as a Bachelor’s of Science in Nursing from the University of Massachusetts.

Michael Monovoukas is the co-founder and CEO of AcuityMD. Prior to launching AcuityMD, he was a Medtech entrepreneur. He also held a leadership role at PatientPing, a leading provider of care coordination software. Michael started his career as a management consultant at Bain & Company, where he advised leading life sciences companies on growth and commercial strategy. Michael received his M.B.A. from Harvard Business School and his B.A. in Public Policy and Finance from Princeton University. He can be reached at mike@acuitymd.com.

Mehul Desai leads global medical affairs and advocacy at Enable Injections. He drives evidence generation, scientific communications, and KOL engagement for the enFuse® technology, while supporting regulatory approvals and current and prospective partnerships. A frequent author and presenter on subcutaneous drug delivery, Mehul has contributed to peer-reviewed journals, trade publications, and industry conferences, advancing the science of large-volume biologics administration.

He brings deep biopharma experience in rare disease, having contributed to the success of multiple blockbuster therapies. At argenx, he served as Medical Director, shaping strategic direction, supporting clinical trial execution, and advancing business development across multiple therapeutic areas. Earlier in his career, he held field medical roles at Alexion Pharmaceuticals and Mallinckrodt Pharmaceuticals, both supporting rare disease portfolios.

Mehul earned his Doctor of Pharmacy from Purdue University and completed his post-doctoral medical affairs fellowship at Johnson & Johnson.

Carlos is a global commercial leader with 17 years of experience driving Sales and Downstream Marketing for Class III minimally invasive and surgical medical devices. Throughout his career, he has successfully navigated both the agile startup environment and the complex corporate matrix. Carlos has managed functional and regional high-performing teams with a proven record of capturing market share and driving revenue, maintained by a relentless, laser-focus on customer orientation. Chris is an enthusiastic, customer-centric global MedTech leader with a passion for translating

innovations to patients. He has a deep understanding of the European and US Ortho and Spine

markets and is a strong advocate for talent development and patient-centric technology innovation.

Chris began his career with Johnson & Johnson in 2002 in French-speaking Switzerland as a Sales

Consultant, and over the following years he has held several roles with increasing responsibility in

Switzerland, Germany and across Europe, Middle-East and Africa within Johnson&Johnson’s

orthopedic and neuro businesses. In 2018, he had the opportunity to move to the Boston area to lead

JnJ’s Spine business in the US.

In 2023, after more than 20 years with Johnson & Johnson, Chris took the role of Chief Commercial

Officer for Nyxoah to prepare the commercialization of a novel neuromodulation device for patients

with severe obstructive sleep apnea.

In beginning 2024, Chris joined icotec Medical Inc as their Chief Executive Officer. Icotec Medical is

a highly innovative medical device company that manufactures and commercializes unique carbon

fiber PEEK implants for patients with complex conditions in the Spine, primarily tumors and

infections. Icotec is growing quickly and is investing heavily in clinical evidence, manufacturing

capabilities and its commercial footprint.

Chris holds a master’s Degree in Chemical Engineering and Biotechnology from the Swiss Federal

Institute of Technology in Lausanne, Switzerland and studied at the Royal Institute of Technology in

Stockholm, Sweden. He has served in the Swiss Army to the level of Captain in the NBC defense

Troops.

Chris currently lives in the Boston, MA area, with his wife and three children. He enjoys skiing, sailing

and any type of mountain activity. He is perfectly fluent in German, French and English.

Chris is an enthusiastic, customer-centric global MedTech leader with a passion for translating innovations to patients. He has a deep understanding of the European and US Ortho and Spine markets and is a strong advocate for talent development and patient-centric technology innovation.

Chris began his career with Johnson & Johnson in 2002 in French-speaking Switzerland as a Sales Consultant, and over the following years he has held several roles with increasing responsibility in Switzerland, Germany and across Europe, Middle-East and Africa within Johnson&Johnson’s orthopedic and neuro businesses. In 2018, he had the opportunity to move to the Boston area to lead JnJ’s Spine business in the US.

In 2023, after more than 20 years with Johnson & Johnson, Chris took the role of Chief Commercial Officer for Nyxoah to prepare the commercialization of a novel neuromodulation device for patients with severe obstructive sleep apnea.

In beginning 2024, Chris joined icotec Medical Inc as their Chief Executive Officer. Icotec Medical is a highly innovative medical device company that manufactures and commercializes unique carbon fiber PEEK implants for patients with complex conditions in the Spine, primarily tumors and infections. Icotec is growing quickly and is investing heavily in clinical evidence, manufacturing capabilities and its commercial footprint.

Chris holds a master’s Degree in Chemical Engineering and Biotechnology from the Swiss Federal Institute of Technology in Lausanne, Switzerland and studied at the Royal Institute of Technology in Stockholm, Sweden. He has served in the Swiss Army to the level of Captain in the NBC defense Troops.

Chris currently lives in the Boston, MA area, with his wife and three children. He enjoys skiing, sailing and any type of mountain activity. He is perfectly fluent in German, French and English.

Thomas Bergamo leads U.S. market access and healthcare policy strategies to advance patient and provider access to AtriCure’s technologies. He and his team work closely with AtriCure’s customers, as well as commercial, medical, regulatory and scientific affairs colleagues on a broad range of upstream and downstream initiatives throughout the product lifecycle. Thomas frequently engages with government and commercial payers, trade associations, medical societies, and patient groups to influence and shape policies affecting adoption of life saving technologies in the cardiovascular space.

Most recently, Thomas served as Senior Director and Global Head of Market Access and Healthcare Policy for Becton Dickinson’s (BD) Interventional Segment where he sat on the Public Affairs Senior Leadership Team. Prior to joining BD, he held positions of increasing responsibility at Second Sight Medical, Boston Scientific, Abbott, and Cochlear. Thomas began his career at Lash Group Healthcare Consultants, holds a BA from Davidson College, and an MBA from UVA’s Darden School of Business.

Holly is a Senior Partner at The Mullings Group, and has been a part of the firm for 25+ years. She believes the most productive and fulfilling organizations are built on the complementary forces that make up a team. Her bidirectional approach to each search allows her to put the best interest of both the individual and the company at the center of her team’s work. She is passionate about the medical device industry, which works to elevate health and healthcare, the individual careers we help build, and the team at TMG. These individuals keep Holly committed to being better every day.

Continuously giving back to the industry, Holly is a member, guest speaker, and advocate for MassMEDIC’s Women in Medtech organization. She also hosts two podcasts, The Power Curve, and Tech Talks with Holly Scott.

Holly is a graduate of the University of Florida with a psychology major and a business minor. She has also been awarded Certified Senior Account Manager (CSAM) by MRINetwork, an international network of recruiting firms.

Dave Carey is CEO of Preceptis Medical, a company dedicated to making ENT procedures simpler and safer for surgeons, patients and parents. Dave is a results-driven executive with over 30 years of experience transforming organizations, scaling businesses, and fostering high-performance cultures in the medical device industry. Known for his ability to align teams with strategic goals, Dave blends visionary leadership with a process-driven approach to deliver exceptional growth and operational excellence.

Prior to Preceptis, Dave served as Chief Commercial Officer at Pristine Surgical, leading the commercialization strategy for the company’s innovative single-use endoscopy platform. His efforts include building U.S. and international sales organizations, defining company m Dave has also built a high-impact culture of accountability by emphasizing cross-functional collaboration marketing, regulatory, and sales operations while developing physician advisory boards and leveraging strategic vendor partnerships.

Dave has a demonstrated track record of transforming underperforming teams into top performers. At Stryker, he transitioned two struggling regional teams into award-winning organizations, achieving revenue objectives for the first time in over a decade and cultivating employee engagement. His leadership fostered a culture of innovation and accountability, resulting in record-breaking sales, operational efficiency, and employee satisfaction. Recognized for his ability to drive diversity and inclusion, Dave was invited to speak at Stryker’s Diversity and Inclusion training events and featured in podcasts for the Stryker Women’s Network.

As a strategic innovator, Dave has led major initiatives such as the global launch of Medtronic’s Endeavor Drug-Eluting Stent, Medtronic Vascular’s first billion-dollar product. He built a comprehensive global strategy to coordinate logistics, training, and marketing across 40 countries, earning Medtronic’s prestigious “Star of Excellence” award.

Beyond his corporate achievements, Dave is a mentor for MassMEDIC’s Ignite program, helping early-stage CEOs build commercial organizations, refine market strategies, and align company culture with growth objectives. His strategic guidance in scaling operations and fostering accountability has helped startups secure funding and achieve sustainable success.

Dave holds an MBA from the University of Rochester with concentrations in Strategy and Marketing, and a BA from SUNY Geneseo in Interpersonal and Organizational Communications. Based in Bedford, New Hampshire, Dave is a proven leader, culture builder, and performance driver in the medical device sector.

Cardiovascular surgeon Dr. Sanjeev Aggarwal currently serves as the Global Chief Medical Officer and Vice President of Surgical Therapies at Johnson and Johnson MedTech- Heart Recovery. Dr. Aggarwal joined Abiomed in 2022 after a distinguished career in cardiothoracic surgery spanning across leadership roles in clinical medicine, innovation, and health system governance. He is passionate about leveraging the intersection of physical and agentic artificial intelligence, data-driven engineering, and the biologic sciences to improve patient outcomes and advance human Health.

Dr. Aggarwal has been internationally recognized for his work in advanced heart failure and valvular heart disease. His clinical areas of interest include cardiac transplantation, mechanical circulatory support, minimally invasive surgery, and transcatheter valve repair and replacement. Dr. Aggarwal has served on multiple institutional, national, and international committees and scientific advisory boards. He has authored and co-authored numerous peer-reviewed articles, abstracts, and book chapters, and has been a principle or co-investigator in several FDA-approved clinical trials.

Prior to joining Abiomed, Dr. Aggarwal served as the Chief of Cardiovascular Surgery and the inaugural Clinical Innovation Officer for Beaumont Health in Michigan. In his role as Clinical Innovation Officer for the health system, Dr. Aggarwal led system wide initiatives around data analytics and population health. He previously was the Director of Cardiac Transplantation and Mechanical Circulatory Support at Saint Luke’s Mid America Heart Institute in Kansas City, MO. Dr. Aggarwal has also held faculty appointments in the Department of Surgery at Columbia University-New York Presbyterian Hospital and the University of Louisville Medical Center. Through his career, Dr. Aggarwal has been a strong advocate for multidisciplinary models of care oriented around disease-based service lines. He has led several initiatives in the fields of predictive analytics and artificial intelligence and their application to medical device technology, longitudinal care models, and clinical workflow optimization.

Dr. Aggarwal earned his undergraduate degree at the University of Pennsylvania, majoring in biology and minoring in chemistry and economics. He earned his medical degree from Baylor College of Medicine in Houston, TX. Dr. Aggarwal completed his residency in general surgery at NYU Langone Medical Center. He then attended the University of Michigan for his cardiothoracic surgical training.

While at the University of Michigan, Dr. Aggarwal was the recipient of a research training grant from the NIH. He also completed an advanced cardiac surgical fellowship in heart transplantation, ventricular assist devices, and minimally invasive surgery at Columbia University-New York Presbyterian hospital in New York. More recently, Dr. Aggarwal earned an M.B.A. with certification in data science, artificial intelligence, and business analytics from the Sloan School of Management at the Massachusetts Institute of Technology.

Liz Proos is the Vice President of Product Development at Daré Bioscience, a company focused on accelerating innovation in women’s health. In this role Ms Proos is responsible for technical and strategic product development, leading a cross-functional R&D and product development team and key strategic external partners, including development of the proprietary DARE Intelligent Drug Delivery System (IDDS) platform technology, which is designed to provide programmable, precise, long-term drug delivery from a subcutaneously implanted device. A Wellesley College (Wellesley, MA, US) graduate, Ms Proos joined Daré as part of the acquisition of Microchips Biotech in November 2019 and has more than 26 years of experience in drug delivery science and product development of combination products and medical devices.

Tom Salemi leads DeviceTalks, a multimedia network the serves the medtech industry’s disruptors. Tom has tracked the medtech industry for over two decades, writing about the sector’s biggest – and smallest players – for organizations including Dow Jones, Elsevier, Informa and American Business City Journals. Today, Tom allows medical device leaders to tell their stories through podcasts and other media. Tom is the creator DeviceTalks Podcast Network, DeviceTalks Tuesday Digital Event Series, and Editorial Director of DeviceTalks Boston, DeviceTalks Minnesota and DeviceTalks West events. He lives on the North Shore of his Massachusetts with his wife, two sons and Daisy the dog.

Kelsey Mayo, Ph.D., is the Co-founder and CEO of Armor Medical Inc., a biomedical device company pioneering wearable innovations that safeguard maternal health. A multidisciplinary scientist and empathetic leader, Dr. Mayo previously helped build one of the world’s largest and most diverse biomedical research datasets as part of the NIH’s All of Us Research Program. She is an award-winning FemTech innovator, recognized as a Change Cultivator 40 Under 40 Global Change Leader and the 2024 MedTech Innovator Early-Stage Grand Prize winner.

At Armor Medical, Dr. Mayo leverages her deep technical expertise—and her lived experience as a hemorrhage survivor—to bring to market the first commercial real-time early warning system for maternal hemorrhage. She is passionate about translating science into equitable, precision health solutions that meaningfully improve outcomes for women and families.

Joe Mullings has been building companies and careers since 1989. He is the Founder, Chairman and CEO of The Mullings Group, including TMG Search and Dragonfly. The search firm, with over three decades in the industry, is responsible for more than 9,000 successful searches in medtech / healthtech / life sciences with clients ranging from multi-billion-dollar companies to emerging high-tech organizations worldwide. TMG’s international presence and work with over 900 companies allow them to provide solutions to the clients they partner with across the globe.

As the first search firm to integrate media and talent access, Dragonfly was launched as a media production company, complete with a state-of-the-art studio, for use by clients and partners for attention and awareness. Dragonfly is the media machine behind the 7-time Telly Award winning video docuseries, “TrueFuture,” of which Joe is the host. He is also the founder of TMGPulse, a MedTech news and opinion website.

Joe is an active member of the medtech and investor community. He sits on industry boards and serves as an adviser to many emerging tech startups and technology accelerators as well as being an angel investor. He holds an engineering degree from The University of Dayton, Ohio.

Slawek Kierner is an accomplished Chief Digital, AI Data and Analytics Officer, lecturer, advisor, investor, and board member. His career spans applied artificial intelligence, scaling digital products and data platforms, and leading large global technology organizations through transformational change.

Currently, Slawek serves as Chief Digital Officer at Olympus, a $6B global MedTech leader, where he heads the Digital Health business unit, responsible for all digital, robotic, and AI execution. Under his leadership, Olympus launched Olysense—a comprehensive, AI-powered platform that streamlines workflow in GI units, integrates seamlessly with hospital systems, and supports a portfolio of FDA-cleared AI Software-as-a-Medical-Device products for cancer detection and quality improvement. He is also spearheading the deployment of generative AI capabilities—both internally to improve operational efficiency, and externally within workflow products to enhance clinical decision-making and productivity. His strategy emphasizes rapid delivery, regulatory readiness, and measurable impact on patient outcomes.

Previously, at Intuitive Surgical, maker of the da Vinci robotic platforms, Slawek served as Senior Vice President, Digital Experiences and Machine Learning Platforms, launching the AI Suite alongside the company’s newest robotic platforms, contributing to a $15B increase in target valuation. He operationally led the global Internet of Medical Things infrastructure connecting more than 10,000 surgical robots, surgical simulation products, and numerous AI use cases that improved product reliability, surgeon education, and patient outcomes.

Before Intuitive, Slawek was Chief Data and Analytics Officer at Humana, where he transitioned the company to cloud computing and built Florence AI—a platform powering hundreds of ML/AI use cases with more than $1B NPV. At Microsoft, he led global data analytics, applied machine learning, insights, and visualization for the Business Applications unit, and was a founding member of the Power BI product team. He began his career at Procter & Gamble, where he spent 11 years as CIO for Central Europe North and leader of the Warsaw Global Tech Hub.

An active angel investor, limited venture partner, and advisor to analytics and health-tech startups, Slawek has influenced over $100M in health-tech funding rounds and contributed to corporate venture investments, including Swan EndoSurgical, Solvemed AI, Spectrum AI, Cohere Health, Oath Surgical, Kela Health, Buoy Health, CGMMe, Empo Health, and Inspiren. He has played a key role in business development and integration of acquired companies for combined deals worth over $5B.

Slawek holds a PhD in Clinical AI Architectures, MSc degrees in Mechatronics and Management, and has attended executive education at Harvard Business School.

Ryan Myers is the CEO of CranioSense, with over 15 years of medical device experience, a PhD in bioengineering focused on neurophysiology, and an MBA in entrepreneurship and M&A. He has led portfolios and companies working on the cutting edge of neuroscience, primarily in minimally invasive and noninvasive diagnostics, monitoring, and interventional platform technologies. At CranioSense he is building a non-invasive platform capable of being a fast, accurate, and inexpensive alternative to invasive procedures, starting with non-invasive intracranial pressure assessment and monitoring.

Ravi is a transformative Global Medtech & Pharma Executive with 25+ years of global leadership experience. Ravi has held many global leadership roles like CEO, APAC Commercial Head, Country GM, VP of Global Product Dev & Innovation for various Medtech, Diagnostics, Pharma and DrugDelivery Devices & Digital Health products. Ravi has been a P&L Owner~$120M globally in APAC/US/EU and he is a Growth Architect, Product Strategy, NPD & Commercial Excellence leader.

His career spans executive roles at top healthcare and life sciences organizations—including Takeda Pharmaceuticals, Transasia Biomedicals, Medtronic, Baxter/Baxalta, and GE Healthcare—where he has led innovation, scaled businesses, and delivered strong financial and operational performance.

At Takeda, as Vice President and Global Head of Device, Digital Innovation & Product Strategy, Ravi has led cross functional device, digital health, and drug delivery platform development, building an integrated ecosystem of connected therapeutics and advanced delivery technologies for patients and diagnostics, automation and robotics for plasma donors. He also stood up an internal MedTech “startup” within a $7.5B business unit (Plasma Derived Therapies), to architect and scale transformative device strategies in complex global settings.

As CEO of Transasia Biomedicals, India’s largest IVD company, he successfully led a 1,000employee organization with full P&L responsibility (~$120M), driving organizational strategy, commercial excellence, manufacturing, R&D, and global expansion. He managed and led run an end-to-end healthcare technology enterprise with both operational rigor and visionary direction.

Ravi’s AsiaPacific Global Marketing leadership at Medtronic included steering a $100M diabetes therapy portfolio across Japan, Korea, ANZ, and Southeast Asia. He led multiple new product launches, advanced regional market development, built patient centric business models, and achieved record setting growth—getting recognized with multiple global CEO awards for transformative leadership and high performance team engagement.

Earlier at Baxter/Baxalta, he led Strategy, Innovation, and P&L for India and APAC markets, where he delivered 40%+ revenue growth, championed business model innovation for chronic care therapies, and developed new patient access models that generated multi-million dollar growth. His experience driving innovation at the intersection of therapeutics and delivery models directly strengthens his fit for modern drug delivery enterprise leadership.

His global marketing leadership at GE Healthcare reinforced his expertise in emerging market innovation, multigenerational product development, and disruptive technology platforms—launching new devices, leading reverse innovation programs, and growing business segments by several hundred percent across Asia, Europe, Africa, and Latin America.

Ravi brings the rare combination of CEO experience, deep drug delivery device expertise, diagnostics, robotics and automation, medical devices-technologies, global market fluency, and a track record of building winning teams and launching breakthrough products across mature and emerging markets.

His passion for patient centric innovation—combined with his ability to convert strategy into disciplined execution—positions him as an exceptional leader for a medical device company shaping the future of innovative new technologies into commercially launched products which can positively impact the lives of many patients globally.

Rahul is a Senior Analyst on the Medtech Insights team at Clarivate, specializing in key orthopedic markets including surgical robotics, trauma devices, small joint and large joint reconstruction, and ambulatory surgery centers (ASCs). He holds a Master of Science in Data Analytics from the University of Western Ontario. Before joining Clarivate, Rahul worked as a healthcare data analyst at a healthcare quality improvement organization, where he supported analytics initiatives related to public health and performance measurement.

Thomas Knox is the Founder and CEO of VitVio, where he’s building ambient sensing and computer vision systems that help reduce administrative burden and drive efficiency. His system captures what’s happening in operating room automatically and turns it into clean documentation and operational automation. Letting staff focus on what’s most important, the patient.

Before VitVio, Thomas helped scale three start-ups that have become unicorns in their space, including a leader in autonomous stores enabling a truly frictionless walk in walk out experience.

He’s now applying that technical expertise and execution mindset to healthcare, bringing high-performance sensing and AI into the most demanding environment there is, the operating room.

Andre LaFreniere leverages his 20 years’ experience in healthcare technology to advance opportunities and solve challenges in healthcare. Andre’s product development and commercialization knowledge spans collaborations with commercial clients across pharmaceuticals, biotechnology, medical devices, diagnostics, and healthcare systems to solve complex problems and change healthcare for the better.

Sonya S. Bhavsar, PhD is a seasoned professional with a robust background in biomedical engineering and a passion for advancing healthcare through innovation. She holds a B.S .in Biomedical Engineering and a M.S. in Mechanical and Nuclear Engineering from Virginia Commonwealth University, along with a Ph.D. in Theoretical Medicine from RWTH Aachen University in Germany. She has over a decade of industry experience in bringing Class 3 medical devices successfully to the market.

Currently serving as the Senior Director of Advanced R&D at Johnson & Johnson MedTech Heart Recovery Division, Dr. Bhavsar spearheads the innovation of novel mechanical circulatory support solutions. Her approach to innovation involves guiding cross-functional teams through the entire product lifecycle, from conceptualization to successful commercialization, with a particular focus on bringing comprehensive therapeutic solutions to market.

Liz Graham joined the MLSC in February of 2026 and currently serves as the Chief Operating Officer. In this role, she oversees the operational effectiveness of the MLSC and partners with the executive team and board to develop and execute the MLSC’s strategy.

Liz is a startup executive who specializes in accelerating high-growth companies to sustainable profitability and scale. Her experience spans AI (Ada IQ), climate tech (Indigo Ag), digital trust services (Notarize), eCommerce (Wayfair), SaaS (HubSpot), and media and technology (Comcast). Liz combines board-level governance experience at public and private companies with hands-on operational leadership. She brings both strategic acumen and execution capabilities to build high-performing teams that deliver results.

Liz is active on several non-profit boards including the global startup accelerator MassChallenge, The Rappaport Institute, an organization dedicated to improving the governance of Greater Boston by strengthening connections among scholars, students & civic leaders, and is a founding member of Women Applying AI. Liz holds an A.B. from Harvard College, a M.St. from the University of Oxford, England (Balliol), and a J.D. from Harvard University.

Ken Rys is a biomedical engineering leader with 17 years of experience developing FDA-approved Class III implantable devices, spanning cardiac systems, neuromodulation, and brain-computer interfaces. Currently VP of Engineering, Tech Ops at Precision Neuroscience, developing the world’s highest-density implantable brain-computer interface — with over 2,000 recording channels — integrating AI/ML to restore autonomy in patients with ALS, quadriplegia, and stroke.

His career spans Medtronic, where he served as reliability lead on the Micra Transcatheter Pacing System (now with 200,000+ implants worldwide), Verily/Google, where he led PMA-track neuromodulation and wearable biosensor programs, and Cambridge Consultants, leading the implantable devices team. He holds degrees from Johns Hopkins and Case Western Reserve University, and is a named inventor on 14 patents.

Amy Siegel is CEO & co-founder of S2N Health, providing end-to-end solutions for accelerating efficient growth for world-leading MedTech companies by delivering fully integrated, AI-powered customer and market intelligence into sales, marketing and business planning workflows. Amy’s 25+ years of experience in the healthcare industry includes VP of Marketing roles at Aspect Medical (Covidien) and Seventh Sense Biosystems, and 10 years of strategy consulting with Health Advances and Monitor Company (Deloitte).

Prior to her healthcare career, Amy was a loan officer and policy analyst with the U.S. Export-Import Bank. Amy earned a B.A. from Tufts University, a Fulbright Scholarship in Germany, and an MA from the Fletcher School of Law and Diplomacy. Amy is involved in several organizations as a mentor, advisor, and guest lecturer, including Harvard iLabs, UCLA, Columbia, BU, Tufts, U. Mass, Advamed, MassMEDIC, MedTech Innovator and German Accelerator.

Dr. Brian Quist is a Senior Director of Research and Development at Smith+Nephew in Sports Medicine. Within the Arthroscopic Enabling Technology group, he leads the Advanced Technology Development, Systems Engineering and Systems Verification groups. In this role, he is helping advance the purpose of Smith+Nephew – “Life Unlimited” – by using technology to take the limits off living for patients and helping medical professionals do the same.

Brian began his career in 2012 as a consultant at the Boston Consulting Group in the Chicago office. In 2015, he became a Project Leader. While at BCG, he focused on healthcare and had experiences in strategy, R&D portfolio optimization, M&A diligence and large-scale operating model transformations.

In 2017, Brian joined Smith+Nephew as the Director of Digital Health supporting the President of R&D. He transitioned into Sports Medicine to start the Systems Engineering and Systems Verification groups in 2019. In 2020, he added management of the Advanced Technology Development group.

Brian has a PhD in Biomedical Engineering from Northwestern University. He was awarded a National Science Foundation Graduate Research Fellowship and a Ruth L. Kirschstein National Research Service Award for Individual Predoctoral Fellows during his doctoral work at Northwestern. He holds a Bachelors degree in mechanical engineering with a minor in bioengineering from the University of Illinois Urbana-Champaign (UIUC). He also holds a certificate for Management for Scientists and Engineers from the Kellogg School of Management at Northwestern University.

Ashley Hawson is Senior Vice President of Innovation and Operations at Cambridge Consultants, where she leads the Healthcare business unit. She advises global medtech companies on the strategy, development, and delivery of highly novel Class II and III devices. Ashley specializes in translating complex technologies into solutions that support simplified workflows and scalable care environments, drawing on expertise in active implantables, neural and physiological interfacing, sensing, and data-driven systems. A Georgia Tech graduate, she has held leadership and academic roles at GE, Tufts University, and Cambridge Consultants, and is recognized for leadership of difficult, first‑of‑their‑kind R&D programs.

Joana Cartocci is the co-founder and Chief Operating Officer of Robeauté, bringing over a decade of experience in operations management and leadership. She has held key roles in multiple deep tech organizations, showcasing her expertise in coordinating complex, multidisciplinary projects. A founding member of Chirurgie 4.0 and former board member of FranceBiotech, Joana is deeply involved in advancing Healthcare innovation. Fluent in six languages, she brings a global perspective to her work, driving operations at Robeauté as they develop a groundbreaking microrobot technology that aims to revolutionize neurosurgery by enabling targeted diagnosis, treatment and monitoring of brain disease.

I’m Amaury Ciurana, CEO and Co-Founder of REEV.

Trained as a French aerospace engineer at ISAE-SUPAERO and shaped by entrepreneurial programs at HEC Paris, École polytechnique, and UC Berkeley, I have always believed that technology should serve those who need it most and create meaningful impact at scale.

That conviction led me to win the €1M Lopez-Loreta Prize and to transform a student project into REEV, a medical robotics company dedicated to reinventing mobility care for millions of people with mobility disorders.

To achieve this mission, we pioneer intelligent wearable robotics that restore freedom of movement, combining lightweight design and intuitive assistance to make everyday mobility effortless and confident.

In just a few years, REEV has grown into a 30-person team across Toulouse and Boston and raised 12M€. I relocated to the US in 2023 to launch our American journey, driven by optimism, resilience, and a commitment to building a more intelligent and dignified future for mobility and care.

Daniel Carballo is an engineer and co-founder of Encora Therapeutics, a venture-backed medical device company developing wearable neuromodulation technology for movement disorders. He has led the company from concept through FDA clearance, overseeing product architecture, clinical trial execution, regulatory strategy, and early commercialization planning. His work centers on advancing non-invasive, wearable therapy to improve function and independence for patients with essential tremor.

Michael is the current Global Vice President of Healthcare Economics, Reimbursement and Market Access for AtriCure, a surgical medical device company focused on Atrial Fibrillation and post surgical pain management. His teams have worked with CMS to create new MS-DRGs, and societies to create new CPT-1 codes, improving patient access.  He currently sits on the Board of Directors for Mass Medic. Prior to his role at AtriCure he held management positions at Boston Scientific, Philips Healthcare, and Medtronic. 

He earned his PhD from the University Florida in Applied Physiology. 

Michael brings nearly 15 years of surgical robotics experience, currently leading the Global Depuy Synthes VELYS™ Spine Robotics platform across upstream product development and downstream commercial strategy at Johnson & Johnson MedTech. His career spans clinical sales through business unit leadership at Mazor Robotics, Medtronic, and J&J. He holds advance business degrees from the University of Notre Dame and University of Maine.